Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 1998CirculationOpen Access

Glycoprotein IIb/IIIa Integrin Blockade

View Full Paper
Ask AI
Bookmark
Share

Population

Patients with coronary artery disease, specifically acute coronary syndromes

Design

Review

Authors

MMMina MadanSunnybrook Health Science CentreSBScott D. BerkowitzVascular MedicineJTJames E. TchengInterventional Cardiology

Discussion

Loading...

Member takes

Implication

GP IIb/IIIa blockade retains niche relevance in high-risk CAD; this review leaves open optimal patient selection and integration with contemporary therapies.

Structured PICO

P
Population
Patients with coronary artery disease, specifically acute coronary syndromes (unstable angina, non-Q-wave myocardial infarction, acute ST-elevation myocardial infarction, and abrupt closure after coronary intervention)
I
Intervention
Glycoprotein IIb/IIIa (GP IIb/IIIa) receptor antagonists

This article reviews the current status, pivotal clinical trials, challenges, and future directions of GP IIb/IIIa blockade in the management of coronary artery disease.

Cite This Study

Madan et al. (1998) studied this question.

synapsesocial.com/papers/6a8a808906e1858e55de9168https://doi.org/10.1161/01.cir.98.23.2629

Topics

Dual antiplatelet therapy
View Full Paper
Ask AI
Bookmark
Share